You can buy or sell Aduro Biotech and other stocks, options, ETFs, and crypto commission-free!
Aduro Biotech, Inc. Common Stock, also called Aduro Biotech, is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Read More Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
52 Week High
52 Week Low
Associated PressMar 7
Aduro Biotech to Present at Two Upcoming Investor Conferences in March
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. BERKELEY, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Aduro management is scheduled to present at the following investor conferences: -- 39th Annual Cowen Health Care Con...
Associated PressFeb 28
Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019
BERKELEY, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that three abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2019, which will be held from March 29 through April 3, 2019 in Atlanta, GA. Presentations will highlight the company’s lead programs, STING agonist ADU-S100, and anti-APRIL antibody BION-1301. Details of the presentations are as follows: Abstract 1202: Tumor cell intrinsic STING signaling demonst...
Associated PressFeb 27
Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results
BERKELEY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an important year for Aduro as we prioritized our core technologies and determined a go-forward strategy that is committed to maintaining a leadership role in the STING and APRIL pathways and advancing our clinical programs in areas of high unmet medical need,” said Stephen T. Isaacs, chairman, president and chief exe...
Expected May 1, After Hours